Yuhan Corp and Sorrento Therapeutics announce closing of a $40M USD Financing for joint venture ImmuneOncia to support advancement of Immuno-Oncology program
[English News] https://globenewswire.com/news-release/2019/02/12/1720647/0/en/Yuhan-Corp-and-Sorrento-Therapeutics-Announce-Closing-of-a-40m-USD-Financing-for-Joint-Venture-ImmuneOncia-to-Support-Advancement-of-Immuno-Oncology-Program.html [Korean News] http://news.mtn.co.kr/newscenter/news_viewer.mtn?gidx=2019021216104393438
Sorrento’s and Yuhan’s joint venture, ImmuneOncia, receives approval to begin clinical trial of anti-PD-L1 monoclonal antibody in South Korea
https://www.globenewswire.com/news-release/2018/02/05/1332835/0/en/Sorrento-s-and-Yuhan-s-Joint-Venture-ImmuneOncia-receives-Approval-to-begin-clinical-trial-of-Anti-PD-L1-Monoclonal-Antibody-in-South-Korea.html
The March 2018 edition of BioPharma Dealmakers
Spotlight on oncology: a trend analysis of the value, volume and development stage of deals shaping the current landscape. https://biopharmadealmakers.nature.com/users/61237-immuneoncia-therapeutics-inc/posts/30982-novel-immunotherapies-to-combine-with-pd-1-pd-l1-treatment
A PD-L1 latecomer hoping to break into the market
https://scrip.pharmaintelligence.informa.com/SC099801/ImmuneOncia-A-PDL1-Latecomer-Hoping-To-Break-Into-The-Market
ImmuneOncia “First anti-PD-L1 immunotherapy drug in Korea, clinical phase next year”
ImmuneOncia “First anti-PD-L1 immunotherapy drug in Korea, clinical phase next year” Yuhan-Sorrento joint venture company, fastest development in Korea.. “Later to expedite the development of ‘macrophage-activating anti-CD47 antibody’” “We plan to apply anti-PD-L1 ‘IMC-001’ antibody [...]
Yuhan Corporation And Sorrento Therapeutics Form Joint Venture Company – ImmuneOncia
https://www.fiercebiotech.com/biotech/yuhan-corporation-and-sorrento-therapeutics-form-joint-venture-company-immuneoncia